Prognostic analysis of the plasma fibrinogen combined with neutrophil‐to‐lymphocyte ratio in patients with non–small cell lung cancer after radical resection

BACKGROUND: To investigate the correlation between the fibrinogen combined with neutrophil‐to‐lymphocyte ratio (F‐NLR) and the clinicopathologic features of non–small cell lung cancer (NSCLC) patients who underwent radical resection. METHODS: This study reviewed the medical records of 289 patients with NSCLC who underwent radical resection. The patients were stratified into three groups based on F‐NLR as follows: patients with low NLR and fibrinogen were group A, patients with high NLR or fibrinogen were group B, and patients with high NLR and fibrinogen were group C. Receiver operating characteristic curve and Youden index were used to determine the cutoff value of the NLR and fibrinogen. Survival curves were described by Kaplan–Meier method and compared by log‐rank test. The univariate and multivariate analyses were performed with the Cox proportional hazard model to identify the prognostic factors. RESULTS: A value of 3.19 was taken as the optimal cutoff value of NLR in this study. A value of 309 was used as the optimal cutoff value of fibrinogen. Cox multivariate analysis showed that tumor, nodes, metastasis (TNM) stage and F‐NLR were independent prognostic factors affecting the survival rate of patients. The first‐, third‐, and fifth‐year survival rates in group A were 99.2%, 96.6%, and 95.0%, respectively. The first‐, third‐, and fifth‐year survival rates in group B were 98.4%, 76.6%, and 63.2%, respectively. The first‐, third‐, and fifth‐year survival rates in group C were 91.3%, 41.1%, and 22.8%, respectively. F‐NLR was significantly correlated with overall survival in patients with NSCLC (p < 0.001). CONCLUSIONS: The F‐NLR level is markedly related to the prognosis of patients with NSCLC undergoing radical surgery. Therefore, closer attention should be given to patients with NSCLC with a high F‐NLR before surgery to provide postoperative adjuvant therapy.